Schizoaffective Disorder

Tovani does not treat this with ketamine

This page is here for honesty and completeness. Ketamine is not an appropriate treatment for Schizoaffective Disorder, and in some cases it is contraindicated. Below is what the condition is and the treatments that genuinely help — and where, if at all, ketamine has any narrow role (usually only for a separate co-occurring depression). If you’re in crisis, call or text 988.

The short version

●Schizoaffective disorder combines the psychosis of schizophrenia (hallucinations, delusions) with major mood episodes (depressive or manic), with psychosis also occurring outside of mood episodes.
●It is treated like its components: antipsychotics for the psychosis, plus mood stabilizers or antidepressants for the mood symptoms, alongside psychosocial support.
●Ketamine is contraindicated because of the psychotic component — NMDA antagonism can worsen or precipitate psychosis.¹
●Tovani does not treat schizoaffective disorder; active psychosis is screened out at eligibility.
●The right care is a psychiatrist experienced in psychotic and mood disorders, not ketamine.
●Even the depressive episodes are managed within psychiatric care that protects against the psychotic vulnerability — not with at-home ketamine.

Clinical definition

Schizoaffective disorder is characterized by an uninterrupted period of illness during which there is a major mood episode (major depressive or manic) concurrent with the symptoms of schizophrenia, plus delusions or hallucinations for two or more weeks in the absence of a major mood episode at some point in the lifetime of the illness, with mood symptoms present for the majority of the illness duration. It sits between schizophrenia and the mood disorders: unlike a mood disorder with psychotic features (where psychosis only occurs during mood episodes), schizoaffective disorder has psychosis that persists independently of mood. It is specified as bipolar type or depressive type. Treatment addresses both domains, and — as with schizophrenia — the psychotic vulnerability makes NMDA-antagonist treatment (ketamine) inappropriate.

How it differs from related conditions

vs. Schizophrenia

Schizophrenia has less prominent or non-defining mood symptoms; schizoaffective disorder has full mood episodes for much of the illness.

vs. Bipolar disorder with psychotic features

There, psychosis occurs only during mood episodes; in schizoaffective disorder, psychosis also occurs outside them.

vs. Major depression with psychotic features

Mood-congruent psychosis confined to the depressive episode, distinct from the independent psychosis of schizoaffective disorder.

First-line treatments

Antipsychotic medication

Targets the psychotic component and is foundational; paliperidone has a specific schizoaffective indication.

Mood stabilizers / antidepressants

Added for the mood episodes, chosen by subtype (bipolar vs depressive) with attention to the psychosis.

Psychosocial support

CBT for psychosis, family education, and supported employment, as in schizophrenia.

ECT in selected severe cases

Effective for severe mood and psychotic symptoms when medications are insufficient.

When standard treatments fail

Treatment-resistant schizoaffective disorder is managed by specialist psychiatry — optimizing antipsychotics (including clozapine), adjusting mood treatment by subtype, considering ECT, and treating substance use. Ketamine is not part of this pathway; the psychotic component contraindicates it.

Where ketamine fits

Ketamine is contraindicated in schizoaffective disorder because of its psychotic component. Like schizophrenia, the disorder involves a vulnerability to psychosis, and ketamine's NMDA-antagonist mechanism can worsen or precipitate psychotic symptoms (Rosburg 2018); active psychosis is a standard contraindication to therapeutic ketamine (Sanacora 2017). Even the depressive episodes of schizoaffective disorder are managed within psychiatric care designed to protect against that psychotic vulnerability — not with at-home ketamine. The honest answer is that this is not an appropriate use of ketamine.

Where this fits with Tovani

Tovani does not treat schizoaffective disorder, and eligibility screening excludes active psychosis for safety. Care belongs with a psychiatrist experienced in psychotic and mood disorders. This page exists to make the answer clear: ketamine is not appropriate here.

Check eligibility Find treatment options The science behind ketamine

Frequently asked

Can ketamine help schizoaffective disorder?

No — it's contraindicated. The disorder includes psychosis, and ketamine's mechanism can worsen or trigger psychotic symptoms. It's not appropriate even for the depressive episodes, which are managed within psychiatric care that protects against the psychotic vulnerability.

How is it different from bipolar disorder?

In bipolar disorder, psychosis (when it occurs) is confined to mood episodes. In schizoaffective disorder, psychotic symptoms also occur outside of mood episodes — which is part of why it's treated more like schizophrenia, with antipsychotics central, and why ketamine is off the table.

What treats schizoaffective disorder?

Antipsychotic medication for the psychosis, plus mood stabilizers or antidepressants for the mood episodes, with psychosocial support — and ECT in selected severe cases. It's managed by specialist psychiatry.

Does Tovani treat this?

No. Active psychosis is screened out for safety, and schizoaffective disorder belongs with a psychiatrist experienced in psychotic and mood disorders. We say so plainly rather than offer an inappropriate treatment.

References

McCutcheon RA et al. 2020, JAMA Psychiatry — Overview of schizophrenia-spectrum psychosis and its treatment, relevant to schizoaffective disorder. (PMID 31664453)
Yatham LN et al. 2018, Bipolar Disorders — CANMAT/ISBD guidelines for the mood-disorder component, relevant to managing the mood episodes of schizoaffective disorder. (PMID 29536616)
Rosburg T & Schmidt A 2018, Frontiers in Behavioral Neuroscience — Mechanisms of ketamine-induced psychotic-like symptoms — the basis for its contraindication in psychotic disorders. (PMID 30618662)

Last reviewed by Dr. Ben Soffer, DO on May 31, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.